Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2015-11-12

FDA Approved: LEDIPASVIR AND SOFOSBUVIR — Supplemental Application (Asegua Therapeutics LLC)

View source ↗

Summary

The FDA approved a supplemental application for ledipasvir/sofosbuvir by Asegua Therapeutics LLC. This action pertains to the hepatitis C treatment indication f…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Ledipasvir/sofosbuvir (Ledipasvir and sofosbuvir)

Snippet

SUPPL AP for LEDIPASVIR AND SOFOSBUVIR (LEDIPASVIR AND SOFOSBUVIR)